We could not confirm an exploratory subgroup analysis of the UK NCRI R-CHOP-21, which demonstrated a nonsignificant trend to better PFS and OS in 50 patients with PMBCL treated with R-CHOP-14 prospectively. 25 Neither do our results support a retrospective analysis of the Lymphoma Study Association (LYSA), which demonstrated inferior PFS and OS of R-CHOP-21 compared with R-CHOP-14 or ACVBP. 26 Rather, the results are in concordance with the overall outcome on the chemotherapy comparison in the UNFOLDER trial.
← all excerpts
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial.
1
—
—